Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Cerus Corporation to Release Fourth Quarter and Full-Year 2024 Financial Results on February 20, 2025


Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus' website and will be available approximately three hours after the call through March 6, 2025.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


These press releases may also interest you

at 19:00
Asia-Pacific private equity shows green shoots of recovery
Despite another year of uncertain macroeconomic conditions, Asia-Pacific's private equity (PE) market is showing signs of recovery after two years of decline as deal value rose 11% to $176 billion in 2024, according to Bain & Company's Asia-Pacific...

at 18:36
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of The AZEK Company Inc.
Rowley Law PLLC is investigating potential securities law violations by The AZEK Company Inc. and its board of directors concerning the proposed acquisition of the company by James Hardie Industries plc . Stockholders will receive $26.45 and 1.0340...

at 18:25
Fortis Inc. Announces Pricing of Senior Unsecured Notes
Fortis Inc. ("Fortis" or the "Corporation") announced today that it has priced an offering by private placement (the "Offering"), pursuant to the exemptions from the prospectus requirements of applicable Canadian securities laws, of $600 million...

at 18:14
TMDX Investors Have Opportunity to Lead TransMedics Group, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead...

at 18:06
TFII Investors Have Opportunity to Lead TFI International Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of TFI International Inc. securities between April 26, 2024 and February 19, 2025, inclusive (the "Class...

at 18:05
Brookfield Corporation Announces Results of Conversion of its Series 38 Preferred Shares
Brookfield Corporation ("Brookfield") today announced that after having taken into account all election notices received by the deadline for the conversion of its Cumulative Class A Preference Shares, Series 38 (the "Series 38 Shares") into...

More news about Business...


News published on and distributed by: